GRI Bio, Inc. (GRI)
Fuera de horario:
GRI Bio, Inc.
2223 Avenida de la Playa
Suite 208
LA Jolla, CA 92037
United States
619 400 1170
https://www.gribio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 4
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. W. Marc Hertz Ph.D. | Co-Founder, CEO, President & Director | 842.01k | N/D | 1970 |
| Dr. Albert Agro Ph.d. | Co-Founder & Chief Medical Officer | 461.1k | N/D | 1965 |
| Ms. Leanne M. Kelly | CFO & Corporate Secretary | 550.93k | N/D | 1977 |
| Dr. Vipin Kumar Chaturvedi Ph.D. | Co-Founder & Chief Scientific Officer | N/D | N/D | 1959 |
Descripción
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase II clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 for the treatment of primary sclerosing cholangitis, and GRI-0729, which are in pre-clinical development. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Gestión corporativa
La calificación ISS Governance QuickScore de GRI Bio, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
